Luye Pharma Group Ltd.
Luye Pharma Group Ltd. (LYPHF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
lyphf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Luye Pharma Group Ltd. (LYPHF) measures how much investors pay for each dollar of the company's trailing earnings. LYPHF's current PE ratio of 10.46x is calculated by dividing its stock price of $0.20 by its TTM earnings per share of $0.15. −52.8% discount vs 5Y avg 22.1x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 19 fiscal years · Front-end computedMinQ1 · 25%21.4x
MedianQ3 · 75%57.5x
Max
At 10.46x, LYPHF's current P/E is lower than in 0% of its annual fiscal year readings over the past 19 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - General · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Luye Pharma Group Ltd.You LYPHF | $815M | 10.46x | -70.3% | $0.15 |
 Adcock Ingram Holdings Limited AIHLF | $624M | 7.40x | -79.0% | $5.85 |
 Biotage AB (publ) BITGF | $1.2B | 46.23x | +31.4% | $3.55 |
 Biotest AG BTTAY | $943M | 66.05x | +87.8% | $0.35 |
 CompuGroup Medical SE & Co. KGaA CMPUY | $1.2B | 33.34x | -5.2% | $0.67 |
 CompuGroup Medical SE & Co. KGaA CMPVF | $1.7B | 52.49x | +49.2% | $0.55 |
 China Shineway Pharmaceutical Group Limited CSWYF | $758M | 5.56x | -84.2% | $1.26 |
Industry Average 6 peers with valid PE | — | 35.18x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 17.64x | $0.15 | -11.8% | |
2024-12-31 FY2024 | 20.00x | $0.13 | -6.0% | |
2023-12-31 FY2023 | 21.27x | $0.14 | -28.5% | |
2022-12-31 FY2022 | 29.77x | $0.17 | — | |
2021-12-31 FY2021 | — | $-0.04 | — | |
2020-12-31 FY2020 | 22.08x | $0.22 | +93.8% | |
2019-12-31 FY2019 | 11.39x | $0.46 | -10.3% | |
2018-12-31 FY2018 | 12.69x | $0.41 | -21.6% | |
2017-12-31 FY2017 | 16.20x | $0.30 | -16.5% | |
2016-12-31 FY2016 | 19.40x | $0.27 | -9.5% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Luye Pharma Group Ltd. (LYPHF) measures how much investors pay for each dollar of the company's trailing earnings. LYPHF's current PE ratio of 10.46x is calculated by dividing its stock price of $0.20 by its TTM earnings per share of $0.15.
Frequently asked questions
LYPHF pe ratio · 6 questionsLYPHF's current PE ratio is 10.46x as of 2026-06-15, based on a stock price of $0.20 and TTM EPS of $0.15. Data sourced from Financial Modeling Prep via LYPHF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Luye Pharma Group Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-15